Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 12, 2017, Pages 1922-1930

  Ito, Kiyoaki ^a   Murotani, Kenta ^a   Nakade, Yukiomi ^a   Inoue, Tadahisa ^a   Nakao, Haruhisa ^a   Sumida, Yoshio ^a   Kamada, Yoshihiro ^b   Yoneda, Masashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

hepatitis B virus; hepatitis C virus; liver biopsy; Mac 2 binding protein; Wisteria floribunda agglutinin

Indexed keywords

AGGLUTININ; BINDING PROTEIN; BIOLOGICAL MARKER; MAC 2 BINDING PROTEIN; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ARTICLE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY; BIBLIOGRAPHIC DATABASE; BLOOD; CHRONIC DISEASE; LIVER TUMOR; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE;

ANTIGENS, NEOPLASM; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; DATABASES, BIBLIOGRAPHIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, N-ACETYLGLUCOSAMINE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 85033483636     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13802     Document Type: Article

References (41)

1. Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev. Cell 2002; 3: 99–111.
2. Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin. Liver Dis. 2011; 31: 82–90.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.
4. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999; 30: 1529–1530.
5. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495–500.
6. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–526.
7. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002; 97: 2614–2618.
8. Oberti F, Valsesia E, Pilette C et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609–1616.
9. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 2004; 99: 1160–1174.
10. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48–54.
11. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–350.
12. Kuno A, Ikehara Y, Tanaka Y et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci. Rep. 2013; 3: 1065.
13. Kuno A, Sato T, Shimazaki H et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin. Appl. 2013; 7: 642–647.
14. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563–1570.
15. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
16. Whiting PF, Rutjes AW, Westwood ME et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011; 155: 529–536.
17. Fujiyoshi M, Kuno A, Gotoh M et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J. Gastroenterol. 2015; 50: 1134–1144.
18. +)-M2BP), for assessing liver fibrosis. J. Gastroenterol. 2015; 50: 76–84.
19. Tamaki N, Kurosaki M, Kuno A et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol. Res. 2015; 45: E82–8.
20. Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J. Gastroenterol. 2015; 50: 776–784.
21. Umemura T, Joshita S, Sekiguchi T et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am. J. Gastroenterol. 2015; 110: 857–864.
22. Hanai T, Shiraki M, Ohnishi S et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol. Res. 2015; 45: 1083–1090.
23. Sasaki R, Yamasaki K, Abiru S et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015; 10: e0129053.
24. +-M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2016; 36: 293–301.
25. Nishikawa H, Enomoto H, Iwata Y et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol. Res. 2016; 46: 613–621.
26. Nishikawa H, Enomoto H, Iwata Y et al. Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-gamma-inducible protein-10 in primary biliary cirrhosis. Hepatol. Res. 2016; 46: 575–583.
27. Nishikawa H, Enomoto H, Iwata Y et al. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level in non-alcoholic steatohepatitis. Hepatol. Res. 2016; 46: 1194–1202.
28. Ishii A, Nishikawa H, Enomoto H et al. Clinical implication of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment naive chronic hepatitis B. Hepatol. Res. 2016. https://doi.org/10.1111/hepr.12703. [Epub ahead of print].
29. Ichikawa Y, Joshita S, Umemura T et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol. Res. 2016. https://doi.org/10.1111/hepr.12712. [Epub ahead of print].
30. Heo JY, Kim SU, Kim BK et al. Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus. Medicine (Baltimore) 2016; 95: e3328.
31. Nishikawa H, Takata R, Enomoto H et al. Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C. Hepatol. Res. 2016; 95: e4679.
32. +-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int. 2017; 37: 35–44.
33. Nishikawa H, Enomoto H, Iwata Y et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J. Viral Hepat. 2016; 23: 977–984.
34. Nishikawa H, Hasegawa K, Ishii A et al. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) 2016; 95: e4679.
35. Yamada N, Sanada Y, Tashiro M et al. Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J. Gastroenterol. 2017; 52: 245–252.
36. Huang Y, Adams LA, Joseph J, Bulsara MK, Jeffrey GP. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int. 2017; 37: 121–131.
37. Ito K, Kuno A, Ikehara Y et al. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012; 56: 1448–1456.
38. Artini M, Natoli C, Tinari N et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J. Hepatol. 1996; 25: 212–217.
39. Muir AJ, Naggie S. Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients? Clin. Gastroenterol. Hepatol. 2015; 13: 2166–2172.
40. Asahina Y, Tsuchiya K, Nishimura T et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253–1262.
41. Nagaoki Y, Aikata H, Nakano N et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J. Gastroenterol. Hepatol. 2016; 31: 1009–1015.